As previously

reported

Adjustment

As restated

Balance Sheet as of October 14, 2020

Warrant derivative liability

$

 —

$

28,030,000

$

28,030,000

Total liabilities

19,092,923

28,030,000

47,122,923

Class A common stock subject to possible redemption

477,874,167

(28,030,000)

449,844,167

Class A commmon stock

221

281

502

Additional paid-in capital

5,002,872

1,045,834

6,048,706

Accumulated deficit

(2,451)

(1,046,115)

(1,048,566)

Balance Sheet as of December 31, 2020

Warrant derivative liability

$

 —

$

55,720,000

$

55,720,000

Total liabilities

17,627,450

55,720,000

73,347,450

Class A common stock subject to possible redemption

478,574,408

(55,720,000)

422,854,408

Class A commmon stock

215

557

772

Additional paid-in capital

5,152,825

28,735,558

33,888,383

Accumulated deficit

(154,280)

(28,736,115)

(28,890,395)

Statement of Operations as of December 31, 2020

General and administrative expenses

$

(232,904)

$

(1,046,115)

$

(1,279,019)

Change in fair value of warrant derivative liability

 —

(27,690,000)

(27,690,000)

Total other income (expense)

78,624

(27,690,000)

(27,611,376)

Net loss

(154,280)

(28,736,115)

(28,890,395)

Basic and diluted loss per share

(0.02)

(2.97)

(2.99)

Statement of Cash Flows as of December 31, 2020

Net loss

$

(154,280)

$

(28,736,115)

$

(28,890,395)

Change in fair value of warrant derivative liability

 —

(27,690,000)

(27,690,000)

Net cash used in operating activities

(211,292)

(1,046,115)

(1,257,407)

Payment for underwriting discounts

(10,000,000)

1,046,115

(8,953,885)

Net cash provided by financing activites

501,228,698

1,046,115

502,274,813